Sunesis Pharmaceuticals, Inc. (SNSS) Position Held by Boxer Capital LLC

Boxer Capital LLC maintained its position in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) during the first quarter, Holdings Channel reports. The fund owned 525,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Sunesis Pharmaceuticals makes up about 0.5% of Boxer Capital LLC’s holdings, making the stock its 21st largest position. Boxer Capital LLC’s holdings in Sunesis Pharmaceuticals were worth $2,153,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 1,230 shares during the period. Morgan Stanley increased its position in shares of Sunesis Pharmaceuticals by 768.1% in the first quarter. Morgan Stanley now owns 34,080 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 30,154 shares during the period. Geode Capital Management LLC increased its position in shares of Sunesis Pharmaceuticals by 9.8% in the first quarter. Geode Capital Management LLC now owns 62,353 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 5,571 shares during the period. Vanguard Group Inc. increased its position in shares of Sunesis Pharmaceuticals by 35.0% in the first quarter. Vanguard Group Inc. now owns 581,940 shares of the biopharmaceutical company’s stock worth $2,386,000 after buying an additional 150,994 shares during the period. Finally, Neuberger Berman Group LLC increased its position in shares of Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 20,000 shares during the period. Hedge funds and other institutional investors own 55.47% of the company’s stock.

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc. (SNSS) traded down 3.16% during mid-day trading on Friday, hitting $2.76. The stock had a trading volume of 28,329 shares. The stock’s 50-day moving average is $3.13 and its 200 day moving average is $3.76. Sunesis Pharmaceuticals, Inc. has a 52 week low of $2.73 and a 52 week high of $6.30. The company’s market capitalization is $59.23 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.36. The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts forecast that Sunesis Pharmaceuticals, Inc. will post ($2.08) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.wkrb13.com/markets/2228929/sunesis-pharmaceuticals-inc-snss-position-held-by-boxer-capital-llc.html.

A number of research analysts have commented on the company. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th. Cantor Fitzgerald restated a “hold” rating and issued a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 2nd.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228929/sunesis-pharmaceuticals-inc-snss-position-held-by-boxer-capital-llc.html

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.